Compare Recursion Pharmaceuticals Inc (RXRX) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs STMicroelectronics NV — how do they compare? Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B), while STMicroelectronics NV trades at $53.56 (market cap $50.29B). The key difference: STMicroelectronics NV is far larger — about 21.8× Recursion Pharmaceuticals Inc's market cap, and STMicroelectronics NV pays a 0.64% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and STMicroelectronics NV for 66 Days on average.
| RXRX | STM | |
|---|---|---|
Market Cap | $2.31B | $50.29B |
Volume | 40,478,768 | 9,536,788 |
Sector | Health | Technology |
52-Week High | $6.79 | $79.91 |
52-Week Low | $2.84 | $21.20 |
Typical Hold Time | 22 Days | 66 Days |
Enterprise Value | $1.83B | $47.81B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
STM trades at $56.18, down 4.33% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish technical signal with support near $56, but faces headwinds from recent earnings misses and negative net income margins. Revenue has declined from $17.3B in 2023 to $11.8B in 2025, though AI data-center growth offers a potential catalyst, with the company targeting over $2B in AI revenue by 2027 according to Reuters on 2026-09-09.
The outlook is cautiously optimistic, driven by analyst consensus favoring a Buy rating and a $77.31 price target, implying significant upside. However, risks include volatile profitability, high P/E of 101.89, and dependence on cyclical semiconductor demand. Near-term performance hinges on Q3 2026 earnings versus the $0.40 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
